Beremagene geperpavec clinical trials
How each study uses beremagene geperpavec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 19 May 2023 · VYJUVEK · BLA 125774 (FDA, Purple Book)
- European Union
- 23 Apr 2025 · Vyjuvek · EMEA/H/C/006330 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Krystal Biotech, Inc. (3)
Studies
Open first, then newest update. How each study uses beremagene geperpavec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Long-term Treatment With B-VEC for Dystrophic Epidermolysis BullosaCompletedPhase 3Krystal Biotech, Inc.NCT04917874Written as Open Label Topical Beremagene Geperpavec (B-VEC)
- Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEBCompletedPhase 3Krystal Biotech, Inc.NCT04491604Written as Topical Beremagene Geperpavec
- A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB PatientsCompletedPhase 1/2Krystal Biotech, Inc.NCT03536143Written as Topical beremagene geperpavec
Codes
What other systems call beremagene geperpavec · ClinicalTrials.gg INT002141
- MeSH (NLM) C000731813beremagene geperpavecOne source NLM
- UNII (FDA) AQN7K24KQUBEREMAGENE GEPERPAVECConfirmed FDA, NLM
- NCI Thesaurus C174623Beremagene GeperpavecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731813 | beremagene geperpavec | One source NLM |
| UNII (FDA) | AQN7K24KQU | BEREMAGENE GEPERPAVEC | Confirmed FDA, NLM |
| NCI Thesaurus | C174623 | Beremagene Geperpavec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.